 |
 |
Journal articles
Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study
Abstract : BACKGROUND: Pancreatic adenocarcinoma (PA) is diagnosed in most cases at an advanced stage requiring chemotherapy. Folfirinox is the standard first-line treatment. After Folfirinox failure, gemcitabine alone is routinely used as second-line therapy without data supporting this attitude.AIM: Determine the response rate and outcome of patients with advanced PA treated with gemcitabine after Folfirinox failure.METHODS: We retrospectively analyzed all consecutive patients treated with gemcitabine after Folfirinox failure for a locally advanced or metastatic PA between 2009 and 2015. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Response rate, control rate and tolerability were assessed.RESULTS: 96 patients were included (male, 51%; median age, 62; performance status (PS) 0-1, 47%). Median duration on gemcitabine was 2.1 months. The overall disease control rate was 40%. Median OS was 3.7 months (95%CI: 2.5-5.2) and median PFS was 2.1 months (95%CI: 2.0-2.6). Reasons for treatment discontinuation were mostly progression (51%). Age at diagnosis and PS were independently associated with OS in multivariate analysis (HR of 1.86; p=0.0055 and 2.42; p<0.0001 respectively). 34 patients experienced a grade 3 adverse event.CONCLUSIONS: This study suggests that gemcitabine is not beneficial to all patients failing on Folfirinox first-line therapy and should be restricted to young patients with good PS.
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01534249
Contributor : Laurent Jonchère <>
Submitted on : Tuesday, July 4, 2017 - 3:24:28 PM
Last modification on : Wednesday, March 27, 2019 - 2:59:59 PM
Long-term archiving on: : Thursday, December 14, 2017 - 10:44:46 PM
Contributor : Laurent Jonchère <>
Submitted on : Tuesday, July 4, 2017 - 3:24:28 PM
Last modification on : Wednesday, March 27, 2019 - 2:59:59 PM
Long-term archiving on: : Thursday, December 14, 2017 - 10:44:46 PM
File
Viaud et al. - Gemcitabine as ...
Files produced by the author(s)